IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: William J. Curatolo, et al.

Examiner:

To Be Assigne

APPLICATION NO.: To Be Assigned

:Group Art Unit: To Be Assigned

FILING DATE: Herewith

TITLE: Controlled-Release Dosage Forms of

Azithromycin

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: MAY 22, 2000

Attorney for Applicant(s)

Reg. No. 30,561

Pfizer Inc. Patent Department, Box 519 Eastern Point Road Groton, CT 06340 (860) 441-4903